Research Article
A Methodologic Comparison of Invader and Autogenomics INFINITI in Factor-V Leiden and Prothrombin Gene Mutation Testing
Weyant GW*, Newell JM, Benko FA and Donaldson KJ
Department of Pathology, Penn State Milton S. Hershey Medical Center, Hershey, USA
- Corresponding Author:
- Weyant GW
Department of Pathology
Penn State Milton S Hershey Medical Center
Hershey, USA
Tel: 717 531-8246
Fax: 717531-7741
E-mail: gweyant@hmc.psu.edu
Received date: February 03, 2014; Accepted date: February 20, 2014; Published date: February 25, 2014
Citation: Weyant GW, Newell JM, Benko FA, Donaldson KJ (2014) A Methodologic Comparison of Invader and Autogenomics INFINITI in Factor-V Leiden and Prothrombin Gene Mutation Testing. J Clin Diagn Res 2:104. doi:10.4172/jcdr.1000104
Copyright: © 2014 Weyant GW, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Abstract
Background: Collectively, factor V Leiden (FVL, rs6025) and prothromin gene mutation (PGM, rs1799963) are responsible for the majority of inherited thrombophilic states in Caucasians. Patients with inherited thrombophilias are at a greater risk of unprovoked venous thromboembolic events. As such, testing for these abnormalities has become standard of care in the appropriate clinical context.
In this study, we compare the workflow and performance of a non-PCR based method, the Invader® assay, and the INFINITI® assay in FVL and PGM testing. The driving factor behind the methodological comparison was the need to gain efficiency in our molecular diagnostic pipeline. If viable, the INFINITI® platform would allow for rapid expansion of the menu of molecular diagnostic tests performed by our institution.
Methods: To establish concordance between the two assays, forty four and thirty one specimens that had been previously tested with the Invader® assay for FVL and PGM, respectively, were identified.These specimens were subsequently tested on the INFINITI® platform, and results from the two assays were compared.
Results: The INFINITI® Assay produced 100% concordance with the Invader® assay in both FVL (44/44) and PGM (31/31) testing.
Conclusion: These results indicate that the INFINITI® platforms can reliably genotype FVL and PGM.
